The Vigabatrin REMS Program is called for by the FDA to ensure educated risk-benefit choices prior to starting treatment, and to make certain suitable use of vigabatrin while individuals are treated. When vision loss will occur, it is not possible for your health care carrier to recognize.
It is advised that your doctor test your (or your youngster's) vision before or within 4 weeks after starting SABRIL and at least every 3 months during therapy until SABRIL is quit. If you or your kid have any type of side effect that bothers you or that does not go away, inform your healthcare provider.
Tell your doctor if you are pregnant or plan to get pregnant. If vision screening can not be done, your doctor may continue recommending SABRIL, but will not be able to look for any kind of vision loss. Your medical care service provider may quit recommending SABRIL for you (or your child)if vision examinations are not done consistently.